LETTER TO THE EDITOR
Successful treatment of nail psoriasis by switching to a TYK2 inhibitor after cyclosporine
Yuji Kan,
Yuji Kan
Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan
Search for more papers by this author Kouhei Horimoto,
Kouhei Horimoto
Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan
Search for more papers by this author Hisashi Uhara,
Corresponding Author
Hisashi Uhara
Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan
Correspondence
Hisashi Uhara, Department of Dermatology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, Sapporo 060-8543, Japan.
Email: [email protected]
Search for more papers by this author
Yuji Kan,
Yuji Kan
Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan
Search for more papers by this author Kouhei Horimoto,
Kouhei Horimoto
Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan
Search for more papers by this author Hisashi Uhara,
Corresponding Author
Hisashi Uhara
Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan
Correspondence
Hisashi Uhara, Department of Dermatology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, Sapporo 060-8543, Japan.
Email: [email protected]
Search for more papers by this author
First published: 30 September 2024
No abstract is available for this article.
REFERENCES
- 1Hoy SM. Deucravacitinib: first approval. Drugs. 2022; 82: 1671–1679.
- 2Jonathan KH, Ricardo JW, Lipner SR. Efficacy and safety of nail psoriasis targeted therapies: a systematic review. Am J Clin Dermatol. 2023; 24: 695–720.
- 3Imafuku S, Okubo Y, Tada Y, Ohtsuki M, Colston E, Napoli A, et al. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: efficacy and safety results from an open-label, phase 3 trial. J Dermatol. 2024; 51: 365–379.
- 4Hadeler E, Mosca M, Hong J, Brownstone N, Bhutani T, Liao W. Nail psoriasis: a review of effective therapies and recommendations for management. Dermatol Ther. 2021; 11: 799–831.
- 5Sobolewski P, Walecka I, Dopytalska K. Nail involvement in psoriatic arthritis. Reumatologia. 2017; 55: 131–135.
